Back to Search
Start Over
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
- Source :
- Business Wire. June 25, 2024
- Publication Year :
- 2024
-
Abstract
- NEWTON, Mass. -- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the completion [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.798743592